PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$114.86
as of November 20, 2026 -
YTD RETURNS13.31%
as of November 20, 2026 -
Total Net Assets$1.02B
as of November 20, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 9.48 | 8.49 | 17.71 | 31.59 | 18.94 | 11.85 | 10.78 | 10.62 |
| PPH (Market Price) | 9.37 | 8.45 | 17.66 | 31.57 | 18.95 | 11.84 | 10.78 | 10.69 |
| MVIS US Listed Pharmaceutical 25 Index | 9.49 | 8.52 | 17.51 | 31.39 | 18.58 | 11.49 | 10.51 | 10.43 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | -3.28 | 0.50 | 7.51 | 23.60 | 13.35 | 10.67 | 8.69 | 10.00 |
| PPH (Market Price) | -3.19 | 0.67 | 7.58 | 23.72 | 13.37 | 10.65 | 8.70 | 10.09 |
| MVIS US Listed Pharmaceutical 25 Index | -3.26 | 0.55 | 7.32 | 23.42 | 13.00 | 10.31 | 8.44 | 9.81 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 11/19/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
22.99 |
234,916,532 |
|
MRK |
Merck & Co Inc |
11.58 |
118,349,514 |
|
NVO |
Novo Nordisk A/S |
5.46 |
55,822,179 |
|
MCK |
Mckesson Corp |
5.13 |
52,387,856 |
|
PFE |
Pfizer Inc |
4.74 |
48,443,080 |
|
COR |
Cencora Inc |
4.54 |
46,417,508 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
4.40 |
44,968,934 |
|
BMY |
Bristol-Myers Squibb Co |
4.33 |
44,260,458 |
|
GSK |
Gsk Plc |
4.23 |
43,246,065 |
|
ABBV |
Abbvie Inc |
3.74 |
38,211,835 |
|
AZN |
Astrazeneca Plc |
3.70 |
37,795,242 |
|
NVS |
Novartis Ag |
3.64 |
37,194,676 |
|
SNY |
Sanofi Sa/France |
3.56 |
36,347,005 |
|
HLN |
Haleon Plc |
3.53 |
36,080,223 |
|
JNJ |
Johnson & Johnson |
3.31 |
33,822,328 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
3.04 |
31,026,130 |
|
ZTS |
Zoetis Inc |
2.72 |
27,796,607 |
|
VTRS |
Viatris Inc |
1.60 |
16,365,375 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.28 |
13,104,768 |
|
ELAN |
Elanco Animal Health Inc |
0.56 |
5,676,142 |
|
AXSM |
Axsome Therapeutics Inc |
0.51 |
5,242,675 |
|
CORT |
Corcept Therapeutics Inc |
0.41 |
4,220,061 |
|
DFTX |
Definium Therapeutics Inc |
0.36 |
3,674,151 |
|
OGN |
Organon & Co |
0.28 |
2,849,227 |
|
PRGO |
Perrigo Co Plc |
0.11 |
1,126,104 |
|
-USD CASH- |
-- |
-0.00 |
-5,085 |
|
-- |
Other/Cash |
0.24 |
2,461,816 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 10/31/2026
-
Sector
% of Net Assets -
Health Care
99.90 -
Other/Cash
0.10
Country Weightings (%) as at 10/31/2026
-
Country
% of Net Assets -
United States
68.70 -
United Kingdom
11.27 -
Denmark
5.42 -
Israel
4.63 -
Switzerland
3.73 -
France
3.30 -
Japan
2.86 -
Other/Cash
0.10
Fees
Distributions
as of 11/20/2026
Quarterly
1.66%
1.25%
1.86%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency